Company Overview and News

KLCI off to muted start as key Maybank, CIMB drag

2018-10-16 theedgemarkets
KUALA LUMPUR (Oct 16): The FBM KLCI started off on a muted note this morning against teh backdrop of modest gains at regional markets, as key index-linked heavyweights dragged.
5183 MLYBY PECGF MLYNF BATS 4162 5246 7022 9059 CIMDF GBTKF 1155 1023

TSH’s FFB production expected to expand 7% in FY19

2018-10-09 theedgemarkets
TSH Resources Bhd (Oct 8, RM1.10) Maintain buy with a lower fair value (FV) of RM1.38: We maintain a “buy” on TSH Resources Bhd with a lower FV of RM1.38 per share (versus RM1.48 per share previously), based on a financial year 2019 price-earnings ratio of 22 times.

KLCI trends lower in line with struggling regional markets

2018-09-25 theedgemarkets
KUALA LUMPUR (Sept 25): The FBM KLCI trended lower in line with struggling regional markets, but losses were seen capped.
4634 1023 5183 PECGF 9172 4065 2062 MYPRY 5014 3794 9059 CIMDF

TSH 2Q core PBT at RM31m with robust FFB growth

2018-08-24 theedgemarkets
KUALA LUMPUR: Sabah-based plantation player TSH Resources Bhd’s core profit before tax (PBT) came in at RM31.2 million in the second quarter ended June 30, 2018, as it recorded a revenue of RM232.9 million.

Rising palm oil output a boon for TSH Resources

PETALING JAYA: Rising palm oil output at TSH Resources Bhd helped the company mitigate the impact of lower average crude palm oil (CPO) prices during the second quarter ended June 30.

TSH's 2Q core PBT comes in at RM31m with robust FFB growth

2018-08-23 theedgemarkets
KUALA LUMPUR (Aug 23): Sabah-based plantation player TSH Resources Bhd's core profit before tax (PBT) came in at RM31.2 million in the second quarter ended June 30, 2018 (2QFY18), as it recorded a revenue of RM232.9 million.

TSH Resources sees rising CPO output

KUALA LUMPUR: Rising palm oil output at TSH Resources Bhd helped the company mitigated the impact of lower crude palm oil (CPO) prices in the second quarter ended June 30.

Maybank IB sees lower earnings for plantation sector

PETALING JAYA: Lower earnings are expected for the plantation sector in the upcoming second quarter (Q2’18) results season, says Maybank Investment Bank (IB) Research.
5126 SARKF 9059 5112 5254

TSH Resources Bhd — a strong supporter of education charities

2018-07-23 theedgemarkets
Several first-timers will represent plantation group TSH Resources Bhd — whose philanthropy is driven primarily by its desire to support quality education — in the 18th The Edge Kuala Lumpur Rat Race.

TSH Resources set to gain from Indonesia’s biodiesel mandate

2018-07-09 theedgemarkets
KUALA LUMPUR: TSH Resources Bhd’s large exposure to Indonesia puts it in good stead as the republic ramps up its biodiesel mandate to B25 in 2019.

TSH Resources, Indonesian firm to jointly develop land in North Kalimantan

2018-06-28 theedgemarkets
KUALA LUMPUR (June 28): TSH Resources Bhd will team up with Indonesia's PT Dragon Land to jointly develop a 9,000ha piece of land in Tanah Kuning, Mangkupadi, Bulungan Regency, North Kalimantan in Indonesia into an industrial development.
BSMAF 9059 1818

KL Plantation Index down to eight-year low

Despite climbing 11.83 points to 13,184.84 yesterday, the plantation index was at its lowest since October 2010. Analysts said the multi-year low was in tandem with CPO prices that has been trending downwards.
2291 9059 5012

Planters face wage squeeze

THE labour-intensive oil palm sector will likely face margin pressures from Pakatan Harapan’s election manifesto for a higher minimum wage and to reduce dependence on foreign labour, say analysts.
9059 5222 5012

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...